Scientific References

MSCopilot® Clinical Validation Studies

Core references for clinical performance claims

Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, et al.

MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests

European Journal of Neurology. 2020;27(3):429-436

Core peer-reviewed validation reference. Multicentre, randomised, crossover study comparing MSCopilot® to standard MS tests (MSFC). AUC of 0.92 (vs 0.89 for MSFC), sensitivity of 81% and specificity of 82% for identification of patients with EDSS > 3.5. Assessment of reliability and reproducibility.

DOI: 10.1111/ene.14091PMID: 31538396PubMed

Tanoh IC, Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, et al.

Exploring the relationship between MSCopilot, a multidimensional patient self-assessment digital solution, and the Expanded Disability Status Scale

Multiple Sclerosis and Related Disorders. 2021;55:103164

Main EDSS-alignment reference. Correlation of MSCopilot® scores with EDSS (r=0.65). AUC of 0.92 for discrimination of EDSS > 3.5 vs EDSS ≤3.5 patients. Characterisation of disability dimensions: walking, dexterity, cognition and vision.

DOI: 10.1016/j.msard.2021.103164PMID: 34352512PubMed

Supporting Conference Abstracts

Maillart E, et al.

MSCopilot®, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests. A randomized clinical trial

ECTRIMS 2019 poster / Multiple Sclerosis Journal supplement

Conference abstract supporting Maillart 2020 publication. Description of the multicentre, randomised, crossover design.

View

Maillart E, et al.

Results of the MSCopilot Study

AAN 2019, P3.2-012

Conference abstract documenting early scientific communications of the pivotal validation study.

View

Real-World Studies (MS-DETECT)

Real-world digital biomarker data

MS-DETECT: Evaluation of MSCopilot Detect at home for multiple sclerosis remote monitoring

ClinicalTrials.gov: NCT05816122

Active international study (336 participants, >35 sites, 7 countries). Evaluation of MSCopilot Detect for at-home monitoring: usability, satisfaction, safety and progression detection.

View

Vermersch P, et al.

MSCopilot® digital biomarkers obtained in a real-world setting correlated with their clinical counterparts in the MS-DETECT study

ECTRIMS 2025 poster, P1583

Interim analysis: correlation of at-home MSCopilot® digital biomarkers with their MSFC-4 clinical counterparts.

Graves JS, Vermersch P, Filippi M, et al.

Concurrent Validity of MSCopilot® Digital Biomarkers in Real-world Settings Within the MS-DETECT Study

ACTRIMS Forum 2026, P173

Concurrent validity of digital biomarkers in real-world settings. Moderate-to-strong correlations with MSFC-4 components.

View

Usability and Acceptability

Studies on acceptability and use in clinical practice

Maillart E, et al.

Acceptability in clinical practice of MSCopilot, a smartphone application for digital self-assessment of patients living with multiple sclerosis

ECTRIMS 2018, P702

Majority of respondents favourable to the use of the app in MS care. Marked preference for digital tests over standard tests.

Back to home

Scientific References

MSCopilot® Clinical Validation Studies

Core references for clinical performance claims

Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, et al.

MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests

European Journal of Neurology. 2020;27(3):429-436

DOI: 10.1111/ene.14091PMID: 31538396PubMed

Tanoh IC, Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, et al.

Exploring the relationship between MSCopilot, a multidimensional patient self-assessment digital solution, and the Expanded Disability Status Scale

Multiple Sclerosis and Related Disorders. 2021;55:103164

DOI: 10.1016/j.msard.2021.103164PMID: 34352512PubMed

Supporting Conference Abstracts

Maillart E, et al.

MSCopilot®, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests. A randomized clinical trial

ECTRIMS 2019 poster / Multiple Sclerosis Journal supplement

Conference abstract supporting Maillart 2020 publication. Description of the multicentre, randomised, crossover design.

View

Maillart E, et al.

Results of the MSCopilot Study

AAN 2019, P3.2-012

Conference abstract documenting early scientific communications of the pivotal validation study.

View

Real-World Studies (MS-DETECT)

Real-world digital biomarker data

MS-DETECT: Evaluation of MSCopilot Detect at home for multiple sclerosis remote monitoring

ClinicalTrials.gov: NCT05816122

Active international study (336 participants, >35 sites, 7 countries). Evaluation of MSCopilot Detect for at-home monitoring: usability, satisfaction, safety and progression detection.

View

Vermersch P, et al.

MSCopilot® digital biomarkers obtained in a real-world setting correlated with their clinical counterparts in the MS-DETECT study

ECTRIMS 2025 poster, P1583

Interim analysis: correlation of at-home MSCopilot® digital biomarkers with their MSFC-4 clinical counterparts.

Graves JS, Vermersch P, Filippi M, et al.

Concurrent Validity of MSCopilot® Digital Biomarkers in Real-world Settings Within the MS-DETECT Study

ACTRIMS Forum 2026, P173

Concurrent validity of digital biomarkers in real-world settings. Moderate-to-strong correlations with MSFC-4 components.

View

Usability and Acceptability

Studies on acceptability and use in clinical practice

Maillart E, et al.

Acceptability in clinical practice of MSCopilot, a smartphone application for digital self-assessment of patients living with multiple sclerosis

ECTRIMS 2018, P702

Majority of respondents favourable to the use of the app in MS care. Marked preference for digital tests over standard tests.